<p>最近的万基遗传财报电话会议描绘了公司当前状况和未来前景的复杂图景。尽管公司展示了强大的运营效率和有前景的战略举措，但这些都受到当前收入下降和特定领域挑战的影响，特别是产前检测。尽管面临这些困难，公司对未来的增长潜力仍持乐观态度。</p>
<h2>关键领域的强劲增长</h2>
<p>万基遗传在关键领域报告了显著的增长，其中肿瘤学的 MyRisk 同比增长了 16%，而未受影响的 MyRisk 增长了 11%。此外，GeneSight 的检测量增长了 8%，较 2025 年上半年有所加速。这些数据突显了公司在这些关键领域扩展影响力和有效性的成功。</p>
<h2>高调整毛利率</h2>
<p>公司在第三季度实现了令人印象深刻的 70.1% 的调整毛利率，突显了其运营效率和有利的检测组合。这一高毛利率反映了万基遗传在有效管理成本的同时，保持强大产品供应的能力。</p>
<h2>战略合作伙伴关系和产品发布</h2>
<p>万基遗传正在通过战略合作伙伴关系和产品创新积极追求增长。公司已与 SOPHiA GENETICS 达成合作，并准备在 2026 年推出更新版的 MyRisk 检测和新的 Prolaris 前列腺癌检测。这些举措预计将推动未来的增长，并增强公司的竞争地位。</p>
<h2>积极的调整后 EBITDA 和自由现金流</h2>
<p>公司报告的调整后 EBITDA 为 1030 万美元，调整后自由现金流为 1860 万美元，展示了其盈利能力和现金生成能力。这些财务指标突显了公司强大的运营表现及其持续财务健康的潜力。</p>
<h2>重申 2025 年财务指引</h2>
<p>万基遗传重申了 2025 年的全年收入指引，预计年收入在 8.18 亿至 8.28 亿美元之间。公司还维持了 69.5% 至 70% 的毛利率范围和 2700 万至 3300 万美元的调整后 EBITDA 指引。这一重申表明公司对其战略方向和财务前景的信心。</p>
<h2>收入下降</h2>
<p>尽管有积极的发展，万基遗传在第三季度面临了 4% 的同比收入下降，总额为 2.057 亿美元。这一下降主要归因于与去年相比的挑战性比较以及 UnitedHealthcare 对 GeneSight 覆盖政策变化的影响。</p>
<h2>每次检测平均收入下降</h2>
<p>每次检测的平均收入同比下降了 7%，受到付款方组合变化和 UnitedHealthcare 政策变化的影响。这一下降给公司维持收入增长带来了挑战。</p>
<h2>产前检测的挑战</h2>
<p>传统产前产品的检测量同比持平，表明该领域面临持续挑战。尽管与前几个季度相比有所改善，但公司在实现产前检测显著增长方面仍面临困难。</p>
<h2>前瞻性指引</h2>
<p>展望未来，万基遗传专注于保持盈利能力并通过其癌症护理连续体战略推动增长。公司报告的检测量增长了 3%，其中 MyRisk 肿瘤学和 GeneSight 的检测量显著增长。运营费用同比减少了 100 万美元，展示了对成本管理的严格控制。公司仍致力于其 2025 年的财务指引，并继续投资于战略举措以支持未来增长。</p>
<p>总之，万基遗传的财报电话会议突显了其当前挑战和未来机遇的平衡视角。尽管收入下降和产前检测的挑战构成障碍，但公司强大的运营效率、战略合作伙伴关系和重申的财务指引为乐观提供了基础。投资者和利益相关者将密切关注公司在未来几个季度如何应对这些动态。</p>

万基遗传

<p>万基遗传最近的财报电话会议透露了其业绩的混合信号。公司报告总收入下降 4%，至 2.057 亿美元，主要由于产前检测面临挑战和覆盖政策的变化。然而，它实现了强劲的调整后毛利率，达到 70.1%，并在 MyRisk 和 GeneSight 等关键领域实现了显著的销量增长。万基遗传重申了其 2025 年的收入指引为 8.18 亿至 8.28 亿美元，并计划通过战略合作伙伴关系和产品发布来增强增长。尽管面临当前挑战，公司对未来前景仍持乐观态度</p>

<p>The recent earnings call for Myriad Genetics painted a mixed picture of the company’s current standing and future prospects. While the company showcased strong operational efficiencies and promising strategic initiatives, these were tempered by current revenue declines and challenges in specific segments, particularly prenatal testing. Despite these hurdles, the company remains optimistic about its future growth potential.</p>
<div class="lb-trans"><p>最近的万基遗传财报电话会议描绘了公司当前状况和未来前景的复杂图景。尽管公司展示了强大的运营效率和有前景的战略举措，但这些都受到当前收入下降和特定领域挑战的影响，特别是产前检测。尽管面临这些困难，公司对未来的增长潜力仍持乐观态度。</p>
</div><h2>Strong Volume Growth in Key Segments</h2>
<div class="lb-trans"><h2>关键领域的强劲增长</h2>
</div><p>Myriad Genetics reported notable volume growth in key segments, with MyRisk in oncology experiencing a 16% year-over-year increase and MyRisk for unaffected growing by 11%. Additionally, GeneSight volume rose by 8%, marking an acceleration from the first half of 2025. These figures highlight the company’s success in expanding its reach and effectiveness in these critical areas.</p>
<div class="lb-trans"><p>万基遗传在关键领域报告了显著的增长，其中肿瘤学的 MyRisk 同比增长了 16%，而未受影响的 MyRisk 增长了 11%。此外，GeneSight 的检测量增长了 8%，较 2025 年上半年有所加速。这些数据突显了公司在这些关键领域扩展影响力和有效性的成功。</p>
</div><h2>High Adjusted Gross Margin</h2>
<div class="lb-trans"><h2>高调整毛利率</h2>
</div><p>The company achieved an impressive adjusted gross margin of 70.1% in the third quarter, underscoring its operational efficiency and a favorable test mix. This high margin reflects Myriad Genetics’ ability to manage costs effectively while maintaining a strong product offering.</p>
<div class="lb-trans"><p>公司在第三季度实现了令人印象深刻的 70.1% 的调整毛利率，突显了其运营效率和有利的检测组合。这一高毛利率反映了万基遗传在有效管理成本的同时，保持强大产品供应的能力。</p>
</div><h2>Strategic Partnerships and Product Launches</h2>
<div class="lb-trans"><h2>战略合作伙伴关系和产品发布</h2>
</div><p>Myriad Genetics is actively pursuing growth through strategic partnerships and product innovations. The company has entered into a collaboration with SOPHiA GENETICS and is preparing to launch an updated MyRisk test and a new Prolaris prostate cancer test in 2026. These initiatives are expected to drive future growth and enhance the company’s competitive position.</p>
<div class="lb-trans"><p>万基遗传正在通过战略合作伙伴关系和产品创新积极追求增长。公司已与 SOPHiA GENETICS 达成合作，并准备在 2026 年推出更新版的 MyRisk 检测和新的 Prolaris 前列腺癌检测。这些举措预计将推动未来的增长，并增强公司的竞争地位。</p>
</div><h2>Positive Adjusted EBITDA and Free Cash Flow</h2>
<div class="lb-trans"><h2>积极的调整后 EBITDA 和自由现金流</h2>
</div><p>The company reported an adjusted EBITDA of $10.3 million and adjusted free cash flow of $18.6 million, showcasing its profitability and ability to generate cash. These financial metrics highlight the company’s strong operational performance and its potential for sustained financial health.</p>
<div class="lb-trans"><p>公司报告的调整后 EBITDA 为 1030 万美元，调整后自由现金流为 1860 万美元，展示了其盈利能力和现金生成能力。这些财务指标突显了公司强大的运营表现及其持续财务健康的潜力。</p>
</div><h2>Reaffirmation of 2025 Financial Guidance</h2>
<div class="lb-trans"><h2>重申 2025 年财务指引</h2>
</div><p>Myriad Genetics reaffirmed its full-year revenue guidance for 2025, projecting annual revenue between $818 million and $828 million. The company also maintained its gross margin range of 69.5% to 70% and adjusted EBITDA guidance of $27 million to $33 million. This reaffirmation signals confidence in its strategic direction and financial outlook.</p>
<div class="lb-trans"><p>万基遗传重申了 2025 年的全年收入指引，预计年收入在 8.18 亿至 8.28 亿美元之间。公司还维持了 69.5% 至 70% 的毛利率范围和 2700 万至 3300 万美元的调整后 EBITDA 指引。这一重申表明公司对其战略方向和财务前景的信心。</p>
</div><h2>Revenue Decline</h2>
<div class="lb-trans"><h2>收入下降</h2>
</div><p>Despite the positive developments, Myriad Genetics faced a 4% year-over-year decline in total revenue for the third quarter, amounting to $205.7 million. This decline was primarily attributed to a challenging comparison with the previous year and the impact of UnitedHealthcare’s policy change on GeneSight coverage.</p>
<div class="lb-trans"><p>尽管有积极的发展，万基遗传在第三季度面临了 4% 的同比收入下降，总额为 2.057 亿美元。这一下降主要归因于与去年相比的挑战性比较以及 UnitedHealthcare 对 GeneSight 覆盖政策变化的影响。</p>
</div><h2>Average Revenue Per Test Decrease</h2>
<div class="lb-trans"><h2>每次检测平均收入下降</h2>
</div><p>The average revenue per test decreased by 7% year-over-year, influenced by shifts in payer mix and the policy change by UnitedHealthcare. This decrease presents a challenge that the company needs to address to maintain its revenue growth.</p>
<div class="lb-trans"><p>每次检测的平均收入同比下降了 7%，受到付款方组合变化和 UnitedHealthcare 政策变化的影响。这一下降给公司维持收入增长带来了挑战。</p>
</div><h2>Challenges with Prenatal Testing</h2>
<div class="lb-trans"><h2>产前检测的挑战</h2>
</div><p>The volume growth for legacy prenatal products remained flat year-over-year, indicating ongoing challenges in this segment. Although there were some improvements from previous quarters, the company continues to face hurdles in achieving significant growth in prenatal testing.</p>
<div class="lb-trans"><p>传统产前产品的检测量同比持平，表明该领域面临持续挑战。尽管与前几个季度相比有所改善，但公司在实现产前检测显著增长方面仍面临困难。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指引</h2>
</div><p>Looking ahead, Myriad Genetics is focused on maintaining profitability and driving growth through its cancer care continuum strategy. The company reported a 3% increase in testing volumes, with significant growth in MyRisk oncology and GeneSight volumes. Operating expenses were reduced by $1 million year-over-year, demonstrating a disciplined approach to cost management. The company remains committed to its 2025 financial guidance and continues to invest in strategic initiatives to support future growth.</p>
<div class="lb-trans"><p>展望未来，万基遗传专注于保持盈利能力并通过其癌症护理连续体战略推动增长。公司报告的检测量增长了 3%，其中 MyRisk 肿瘤学和 GeneSight 的检测量显著增长。运营费用同比减少了 100 万美元，展示了对成本管理的严格控制。公司仍致力于其 2025 年的财务指引，并继续投资于战略举措以支持未来增长。</p>
</div><p>In conclusion, Myriad Genetics’ earnings call highlighted a balanced view of its current challenges and future opportunities. While revenue declines and challenges in prenatal testing pose hurdles, the company’s strong operational efficiencies, strategic partnerships, and reaffirmed financial guidance provide a foundation for optimism. Investors and stakeholders will be keenly watching how the company navigates these dynamics in the coming quarters.</p>
<div class="lb-trans"><p>总之，万基遗传的财报电话会议突显了其当前挑战和未来机遇的平衡视角。尽管收入下降和产前检测的挑战构成障碍，但公司强大的运营效率、战略合作伙伴关系和重申的财务指引为乐观提供了基础。投资者和利益相关者将密切关注公司在未来几个季度如何应对这些动态。</p>
</div>

万基遗传的财报电话会议：信号复杂及未来展望